In-person classes will resume for the fall semester. | COVID-19 News & Information

Chemistry and Biochemistry

Carolynn Arpin

Organic Chemistry


University of Toronto, Postdoctoral Researcher
Ph.D. University of Colorado, Boulder, CO
B.S. Georgia Southern University, Statesboro, GA

Research Interests

My background in organic reaction development and current work in medicinal chemistry has steered my own research interests towards the development of innovative synthetic methods and their utilization in building small molecules that inhibit protein-protein interactions of therapeutic relevance. More information can be found on my website(opens in new window).


“NHD2-15, a novel antagonist of Growth Factor Receptor-Bound Protein-2 (GRB2), inhibits leukemic proliferation”. Lewis, T. R.; Smith, J.; Griffin, K.; Aguiar, S.; Rueb, K. F.; Holmberg-Douglas, N.; Sampson, E. M.; Tomasetti, S.; Rodriguez, S.; Stachura, D. L.; Arpin, C. C. PLOS ONE 2020, 15 (8), e0236839.

“CD133+ brain tumour initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence”. Garg, N.; Bakhshinyan, D.; Venugopal, C.: Mahendram, S.; Rosa, D. A.; Vijayakumar, T.; Manoranjan, B.; Hallett, R.; McFarlane, N.; Delaney, K. H.; Kwiecien, J. M.; Arpin, C. C.; Lai, P.-S.; Gómez-Biagi, R. F.; Ali, A. M.; Ajani, O. A.; Hassell, J. A.; Gunning, P. T.; Singh, S. K. Oncogene 2017, 36, 606-617.

“Applying Small Molecule STAT3 Protein Inhibitors as Pancreatic Cancer Therapeutics”. Arpin, C. C.; Mac, S.; Jiang, Y.; Cheng, H.; Grimard, H.; Page, B. D. G.; Kamocka, M. M.; Haftchenary, S.; Su, H.; Ball, D.; Rosa, D. A.; Lai, P.-S.; Gómez-Biagi, R. S.; Ali, A. M.; Rana, R.; Hanenberg, H.; Kerman, K.; McElyea, K. C.; Sandusky, G. E.; Gunning, P. T.; Fishel, M. L. Molecular Cancer Therapeutics2016, 15, 794-805.

“STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation”. Singh, M.; Garg, N.; Venugopal, C.; Hallett, R.; Tokar, T.; McFarlane, N.; Arpin, C. C.; Page, B. D. G.; Haftchenary, S.; Todic, A.; Rosa, D. A.; Lai, P.-S.; Gómez-Biagi, R.; Ali, A. M.; Lewis, A. M.; Geletu, M.; Mahendram, S.; Bakhshinyan, D.; Manoranjan, B.; Vora, P.; Qazi, M.; Murty, N. K.; Hassell, J. A.; Jurisica, I.; Gunning, P. T.; Singh, S. K. Oncotarget 2015, 6, 27461-27477.

“Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia”. Eiring, A. M.; Page, B. D. G.; Kraft, I. L.; Mason, C. C.; Vellore, N. A.; Resetca, D.; Zabriskie, M. S.; Zhang, T. Y.; Khorashad, J. S.; Engar, A. J.; Reynolds, K. R.; Anderson, D. J.; Senina, A.; Pomicter, A. D.; Arpin, C. C.; Ahmad, S.; Heaton, W. L.; Tantravahi, S. K.; Todic, A.; Colaguori, R.; Moriggl, R.; Wilson, D. J.; Baron, R.; O’Hare, T.; Gunning, P. T.; Deininger, M. W. Leukemia 2014, 29, 586-597.

“Progress towards the development of SH2 domain inhibitors”. Arpin, C. C.; Kraskouskya, D.; Duodu, E.; Gunning, P. T. Chemical Society Reviews2013, 42, 3337-3370.

“The Total Synthesis of Dermostatin A”. Zhang, Y.; Arpin, C. C.; Cullen, A. J.; Mitton-Fry, M. J.; Sammakia, T. Journal of Organic Chemistry2011, 76 (19), 7641-7653.

“New Inhibitors of Colony Spreading in Bacillus subtilis and Bacillus anthracis”. Hao, X.; Nguyen, T.; Kearns, D. B.; Arpin, C. C.; Fall, R.; Sammakia, T. Bioorganic and Medicinal Chemistry Letters2011, 21 (18), 5583-5588.


“New Salicylic Acid Derivatives, Pharmaceutically Acceptable Salt Thereof, CompositionThereof and Method of Use Thereof”. Gunning, P. T.; Weiss, S.; Haftchenary, S.; Page, B.D. G.; Arpin, C. C., Cumaraswamy, A. Patent Pending.

Portrait of Carolynn Arpin